Immutrin

Series-A
immutrin.com Biotech & Healthcare Cambridge, United Kingdom 1-10
Total Funding $86.5M
Latest Round $86.5M Series-A
Last Announced Mar 26, 2026
Investors 7 Backers
Decision Makers 5 Verified

About Immutrin

Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Cambridge, United Kingdom
Team Size 1-10
Tracked Since Sep 29, 2026

Web & Domain Identity

Official Website immutrin.com
Domain Registered Date Sep 20, 2019

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $86,450,000 · Series-A

    fundraisingfox.com

  2. Milestone

    Website domain registered

    immutrin.com

Investors & Backers

7
Cambridge Enterprise Ventures
Cambridge Innovation Capital
F-Prime Capital
Frazier Life Sciences
Parkwalk Advisors
Qiming Venture Partners
SR One

Funding History

1 Round
Series-A · Mar 26, 2026

Founders & Leadership

3

Mihriban Tuna

Chief Executive Officer

Work email & phone locked Unlock →

Robert Blaustein

Chief Medical Officer

Work email & phone locked Unlock →

Tolga Hassan

Chief Financial Officer

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts